

sought to be cancelled without prejudice to or disclaimer of the subject matter therein. New claims 21-24 are sought to be added. These changes are believed to introduce no new matter, and their entry is respectfully requested.


In particular, the amendments to claims 1 and 13 find support, *inter alia*, on page 6, lines 4-6 and claim 20 of the present application. The compound 5-[4-[2-(5-ethylpyridin-2-yl)ethoxyl]benzyl]thiadiazolidine-2,4dione (new claim 21) finds support in col. 15, lines 13-14 of U.S. Pat. 5,478,852 (the '852 patent) cited on page 7, lines 12, 16 and 19 of the present application. This patent is incorporated by reference into this application. See page 11, lines 24-25 of the present application. A copy of this patent is being submitted together with the accompanying Supplemental Information Disclosure Statement. The hydrochloride salt of this compound (new claim 22) finds support in col. 15, line 46, of the '853 patent.

The compound 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl]thiadiazolidine-2,4-dione (new claim 23) finds support in col. 15, lines 27-28 of the '852 patent. The maleate salt of this compound (new claim 24) finds support in col. 15, line 58, of the '853 patent.

Applicants submit that the present application is fully in condition for an examination. If the Examiner believes, for any reason, that personal communication will expedite

prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Respectfully submitted,



Robert W. Esmond
Attorney for Applicants
Registration No. 32,893

Date: April 13, 2020

312 Blair Court, N.W.
Vienna, VA 22180
(703)255-7016

P:\USERS\RESMOND\WIN95\Amend